Patient P-02674
Therapy response
Stable
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
64%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S02
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −24% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 71 SC-12 recommended — Supportive Compound SC-12
- Day 72 Patient accepted — Started SC-12 in the companion
- Day 78 GI symptom burden −17% vs expected — Supportive Compound SC-12
- Day 84 Tolerance state changed — Unstable → Improving
- Day 86 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 91 ME-01 recommended — Monitoring Escalation ME-01
- Day 92 Patient accepted — Started ME-01 in the companion
- Day 95 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 86.
Primary contributors, last 14 days
- Treatment adherence-17
- Inflammatory activity-12
- GI instability-11
- Nutritional resilience+9
- Toxicity+2
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −24%
- Supportive Compound SC-12Day 71Result: symptom burden −17%
- Monitoring Escalation ME-01Day 91Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
84%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 87% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 43
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 37/100
- Autonomic recovery ↓25
- WearableResting HR 82 bpm
- Drug metabolism and exposure ↑20
- BloodToxicity index 45
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3 · butyrate capacity 37/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 50 ms
- Sleep
- 6.3 h
- Steps
- 5,605
- Resting HR
- 84 bpm
Daily log: GI score 38, nutritional resilience 50, adherence 56.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02410 | 42% | S01 | GI-04 | improved | 55 |
| P-02054 | 37% | S01 | CR-01 | improved | 57 |
| P-02018 | 36% | S01 | GI-04 | improved | 46 |
| P-02409 | 31% | S01 | SC-12 | no change | 54 |
| P-02307 | 27% | S01 | — | — | 55 |
| P-02550 | 26% | S01 | — | — | 70 |
| P-02598 | 26% | S01 | — | — | 53 |
| P-02217 | 25% | S01 | — | — | 61 |
| P-02276 | 25% | S01 | — | — | 57 |
| P-02437 | 25% | S01 | — | — | 64 |
| P-02568 | 25% | S01 | — | — | 51 |
| P-02681 | 25% | S01 | — | — | 51 |